quizartinib
daiichi sankyo
['quizartinib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)']
quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed flt3-itd+ #aml #eha2022 
Professor of hematology, Universitary hospital of Sidi Bel Abbés.
Head, Hospitalisation and  Geriatric Unit.